Investments
169Portfolio Exits
25Partners & Customers
10About National Cancer Institute
The National Cancer Institute (NCI) is part of the National Institutes of Health (NIH), which is one of 11 agencies that compose the Department of Health and Human Services (HHS). The NCI, established under the National Cancer Institute Act of 1937, is the Federal Government's National Cancer Institute is the principal agency for cancer research and training. The National Cancer Institute coordinates the National Cancer Program, which conducts and supports research, training, health information dissemination, and other programs with respect to the cause, diagnosis, prevention, and treatment of cancer, rehabilitation from cancer, and the continuing care of cancer patients and the families of cancer patients. It was founded in 1937 and is based in Bethesda, Maryland.
Want to inform investors similar to National Cancer Institute about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Latest National Cancer Institute News
Jan 26, 2023
UW Carbone’s expertise in head and neck cancer treatment and research are held in high esteem nationally, as evidenced by the National Cancer Institute awarding UW a Specialized Program of Research Excellence grant in 2016.
National Cancer Institute Investments
169 Investments
National Cancer Institute has made 169 investments. Their latest investment was in Vergent Bioscience as part of their Grant on November 11, 2022.
National Cancer Institute Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
11/29/2022 | Grant | Vergent Bioscience | $2M | Yes | 4 | |
11/11/2022 | Grant - IV | Penn Medicine | $3.5M | No | 1 | |
11/9/2022 | Grant | Kinimmune | $0.4M | Yes | 3 | |
10/21/2022 | Grant | |||||
10/20/2022 | Grant - III |
Date | 11/29/2022 | 11/11/2022 | 11/9/2022 | 10/21/2022 | 10/20/2022 |
|---|---|---|---|---|---|
Round | Grant | Grant - IV | Grant | Grant | Grant - III |
Company | Vergent Bioscience | Penn Medicine | Kinimmune | ||
Amount | $2M | $3.5M | $0.4M | ||
New? | Yes | No | Yes | ||
Co-Investors | |||||
Sources | 4 | 1 | 3 |
National Cancer Institute Portfolio Exits
25 Portfolio Exits
National Cancer Institute has 25 portfolio exits. Their latest portfolio exit was QT Imaging on December 12, 2022.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
12/12/2022 | Acq - Pending | 1 | |||
12/2/2022 | Merger | 9 | |||
12/1/2022 | Acquired | 19 | |||
Date | 12/12/2022 | 12/2/2022 | 12/1/2022 | ||
|---|---|---|---|---|---|
Exit | Acq - Pending | Merger | Acquired | ||
Companies | |||||
Valuation | |||||
Acquirer | |||||
Sources | 1 | 9 | 19 |
National Cancer Institute Partners & Customers
10 Partners and customers
National Cancer Institute has 10 strategic partners and customers. National Cancer Institute recently partnered with Lantern Pharma on December 12, 2022.
Date | Type | Business Partner | Country | News Snippet | Sources |
|---|---|---|---|---|---|
12/23/2022 | Partner | United States | Lantern Pharma’s New Drug Candidate for Mantle Cell Lymphoma Shows Promise Lantern Pharma recently published RADR-driven research , in collaboration with the National Cancer Institute , on foundational insights into how AI can be used to find new indications for cancer drugs in record times with significant reductions in costs . | 1 | |
12/15/2022 | Vendor | Ireland | Accenture ` s federal business arm has won a position on a five-year , $ 137 million blanket purchase agreement with the National Cancer Institute for software engineering and information technology services . | 1 | |
11/29/2022 | Partner | United States | `` Dr. Rosenberg pioneered cancer immunotherapy and cell therapy and we are honored to have him and the National Cancer Institute as collaborators for this study , '' said Sammy Farah , Ph.D. , M.B.A. , President and Chief Executive Officer , Turnstone Biologics Corp . | 1 | |
11/2/2022 | Vendor | ||||
10/18/2022 | Licensee |
Date | 12/23/2022 | 12/15/2022 | 11/29/2022 | 11/2/2022 | 10/18/2022 |
|---|---|---|---|---|---|
Type | Partner | Vendor | Partner | Vendor | Licensee |
Business Partner | |||||
Country | United States | Ireland | United States | ||
News Snippet | Lantern Pharma’s New Drug Candidate for Mantle Cell Lymphoma Shows Promise Lantern Pharma recently published RADR-driven research , in collaboration with the National Cancer Institute , on foundational insights into how AI can be used to find new indications for cancer drugs in record times with significant reductions in costs . | Accenture ` s federal business arm has won a position on a five-year , $ 137 million blanket purchase agreement with the National Cancer Institute for software engineering and information technology services . | `` Dr. Rosenberg pioneered cancer immunotherapy and cell therapy and we are honored to have him and the National Cancer Institute as collaborators for this study , '' said Sammy Farah , Ph.D. , M.B.A. , President and Chief Executive Officer , Turnstone Biologics Corp . | ||
Sources | 1 | 1 | 1 |
National Cancer Institute Team
2 Team Members
National Cancer Institute has 2 team members, including former Chief Information Officer, George Komatsoulis.
Name | Work History | Title | Status |
|---|---|---|---|
George Komatsoulis | Chief Information Officer | Former | |
Name | George Komatsoulis | |
|---|---|---|
Work History | ||
Title | Chief Information Officer | |
Status | Former |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.